Video Experimental Relacionado
Updated: Jul 23, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Primera aplicación clínica de un inhibidor del factor IXa directo activamente reversible como estrategia de
Mauricio G Cohen1, Drew A Purdy, Joseph S Rossi
1Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL 33136, USA. mgcohen@med.miami.edu
Circulation
|July 28, 2010
Resumen
El sistema REG1, dirigido al factor IXa, demostró una anticoagulación controlada y una reversión efectiva en la intervención coronaria percutánea, mostrando una promesa para prevenir eventos isquémicos sin aumentar el riesgo de sangrado.
Área de la Ciencia:
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Farmacología Farmacología.
- Biotecnología La biotecnología es la biotecnología.
Sus antecedentes:
- La necesidad de anticoagulantes que equilibren la prevención de complicaciones isquémicas con el riesgo de sangrado.
- El sistema REG1 ofrece anticoagulación controlada a través de un par de aptameros de ARN (RB006 y RB007).
Objetivo del estudio:
- Evaluar la traducción clínica del sistema REG1 para la anticoagulación y la reversión activa en la intervención coronaria percutánea (ICP).
Principales métodos:
- Estudio de fase 2a con 2 grupos aleatorizados a REG1 o heparina no fraccionada después de la ICP.
- La anticoagulación REG1 (RB006) fue parcial o totalmente revertida con RB007.
- Los puntos finales incluyeron sangrado, eventos isquémicos y medidas farmacodinámicas (tiempo de coagulación activado).
Principales resultados:
- Todos los procedimientos fueron exitosos sin complicaciones trombóticas.
- REG1 mostró 2 eventos isquémicos; heparina no fraccionada mostró 1 evento isquémico y 1 sangrado mayor.
- RB007 efectivamente revirtió RB006, permitiendo la eliminación oportuna de la vaina femoral.
Conclusiones:
- El estudio demostró con éxito la aplicación clínica de la inhibición del factor IXa y la reversión activa con el sistema REG1.
- Esta nueva plataforma anticoagulante proporciona una base para una mayor investigación clínica en entornos de ICP.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...